ERBB2 and cancer: Most of these mutations are in the extracellular domain (ECD) and TKD (about 95% of them), whereas mutations in the transmembrane domain (TMD) and juxtamembrane domain (JMD) together account for less than 15% of all HER2 mutations in cancer [39].